Tune Therapeutics Email Format
Biotechnology ResearchWashington, United States51-200 Employees
Tune Therapeutics is a biotechnology research company based in Durham, North Carolina. It develops epi-therapeutic medicines by using an epigenomic control platform that tunes gene expression up or down without changing the DNA sequence, potentially affecting multiple genes simultaneously. This approach aims to adjust cellular programs toward healthier states and to address cancer, genetic disease, and aging pathways. Its work targets researchers and developers pursuing therapies for complex and chronic diseases lacking curative options. In May 2026, the company presented phase 1b/2a data for TUNE-401 at EASL 2026, reporting clinical evidence of epigenetic silencing in hepatitis B.